We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+54.14%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.52B
AUM Growth
+$24M
Cap. Flow
-$83.5M
Cap. Flow %
-5.5%
Top 10 Hldgs %
56.06%
Holding
84
New
11
Increased
10
Reduced
18
Closed
12

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$39.4M
2
BBIO icon
BridgeBio Pharma
BBIO
+$37.2M
3
AMAM
Ambrx Biopharma Inc
AMAM
+$31M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$28.6M
5
PLRX icon
Pliant Therapeutics
PLRX
+$18.8M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$50.1M
2
RVMD icon
Revolution Medicines
RVMD
+$45.1M
3
ALT icon
Altimmune
ALT
+$42.8M
4
VTYX
Ventyx Biosciences
VTYX
+$35.4M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$20.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
2 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRNA
51
DELISTED
GreenLight Biosciences Holdings, PBC Common Stock
GRNA
$3.97M 0.26%
9,188,659
– –
ICVX
52
DELISTED
Icosavax, Inc. Common Stock
ICVX
$3.73M 0.25%
643,825
– –
ELEV
53
DELISTED
Elevation Oncology
ELEV
$3.71M 0.24%
1,952,032
– –
BCAB icon
54
BioAtla
BCAB
$5.74M
$3.17M 0.21%
23,622
-49,985
-68% -$9M
FULC icon
55
Fulcrum Therapeutics
FULC
$297M
$3.08M 0.2%
+1,081,490
New +$9.69M
PSTX
56
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$3.08M 0.2%
1,000,000
-150,000
-13% -$899K
ELDN icon
57
Eledon Pharmaceuticals
ELDN
$285M
$2.87M 0.19%
1,217,882
– –
ALXO icon
58
ALX Oncology
ALXO
$290M
$2.77M 0.18%
612,079
– –
CNTA
59
DELISTED
Centessa Pharmaceuticals
CNTA
$2.16M 0.14%
561,600
– –
DMRA
60
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$2.03M 0.13%
40,810
– –
TRML
61
DELISTED
Tourmaline Bio
TRML
$1.69M 0.11%
90,065
– –
XFOR icon
62
X4 Pharmaceuticals
XFOR
$460M
$1.42M 0.09%
54,299
– –
BHVN icon
63
Biohaven
BHVN
$2.21B
$1.12M 0.07%
81,963
– –
PYXS icon
64
Pyxis Oncology
PYXS
$236M
$1.09M 0.07%
272,537
-396,317
-59% -$792K
AUTL
65
Autolus Therapeutics
AUTL
$562M
$722K 0.05%
392,167
– –
EYPT icon
66
EyePoint Inc
EYPT
$1.2B
$662K 0.04%
+225,065
New +$803K
CYPH
67
Cypherpunk Technologies Inc
CYPH
$73.3M
$504K 0.03%
+148,151
New +$777K
LENZ
68
LENZ Therapeutics
LENZ
$168M
$489K 0.03%
28,507
– –
CMMB
69
Chemomab Therapeutics
CMMB
$14.1M
$458K 0.03%
72,042
– –
HARP
70
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$402K 0.03%
54,060
– –
BCEL
71
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$364K 0.02%
319,057
– –
ORTX
72
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$138K 0.01%
25,664
-1
-0% -$5
ACET icon
73
Adicet Bio
ACET
$74.7M
– –
-37,500
Closed -$5.36M
ALT icon
74
CALL
Altimmune
ALT
$599M
– –
-400,000
Closed -$6.58M
ALT icon
75
Altimmune
ALT
$599M
– –
-2,600,000
Closed -$42.8M
1 2
3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q1 2023 Portfolio in Review

As of Q1 2023, Cormorant Asset Management held 84 positions worth $1.52B, up 1.6% from $1.49B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Cormorant Asset Management withdrew a net $83.5M in Q1 2023, closing 12 positions and reducing 18 holdings. Its most notable exit was Revolution Medicines, an estimated $45.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

Against the trend, Cormorant Asset Management opened a new position in Enliven Therapeutics worth $42.4M.

  • Cormorant Asset Management's largest Q1 2023 buy was Enliven Therapeutics: 1,936,133 shares worth $42.4M.
  • Cormorant Asset Management added most to BridgeBio Pharma in Q1 2023, an estimated $37.2M increase.
  • Cormorant Asset Management's biggest Q1 2023 reduction was Prometheus Biosciences, Inc. Common Stock, cutting an estimated $50.1M.
  • Cormorant Asset Management fully exited Revolution Medicines in Q1 2023, selling an estimated $45.1M.
  • Cormorant Asset Management's ten largest holdings make up 56% of its $1.52B portfolio in Q1 2023.
  • Cormorant Asset Management opened 11 new positions and closed 12 in Q1 2023.
  • Cormorant Asset Management's portfolio value rose 1.6% quarter-over-quarter to $1.52B.

Based on Cormorant Asset Management's 13F filing for Q1 2023, filed 15 May 2023.